MY199319A - Anti-pd-l1 antibody and use thereof - Google Patents

Anti-pd-l1 antibody and use thereof

Info

Publication number
MY199319A
MY199319A MYPI2019006142A MYPI2019006142A MY199319A MY 199319 A MY199319 A MY 199319A MY PI2019006142 A MYPI2019006142 A MY PI2019006142A MY PI2019006142 A MYPI2019006142 A MY PI2019006142A MY 199319 A MY199319 A MY 199319A
Authority
MY
Malaysia
Prior art keywords
antibodies
fully human
disclosed
affinity
human anti
Prior art date
Application number
MYPI2019006142A
Other languages
English (en)
Inventor
Ting Xu
Lavrovsky Yan
Barbashov Sergei
Repik Alexey
Samsonov Mikhail
Ignatiev Vasily
Archuadze Shorena
Original Assignee
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc
Publication of MY199319A publication Critical patent/MY199319A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MYPI2019006142A 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof MY199319A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18
PCT/US2018/028206 WO2018195226A1 (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Publications (1)

Publication Number Publication Date
MY199319A true MY199319A (en) 2023-10-24

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019006142A MY199319A (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Country Status (17)

Country Link
US (1) US20210115143A1 (enExample)
EP (1) EP3612565A4 (enExample)
JP (2) JP2020517239A (enExample)
KR (1) KR102323960B1 (enExample)
CN (1) CN110856446A (enExample)
AU (1) AU2018256392B2 (enExample)
BR (1) BR112019021828B1 (enExample)
CA (1) CA3059447A1 (enExample)
CL (1) CL2019002953A1 (enExample)
CO (1) CO2019012118A2 (enExample)
EA (1) EA201900443A1 (enExample)
MA (1) MA50038A (enExample)
MX (1) MX2019012461A (enExample)
MY (1) MY199319A (enExample)
PH (1) PH12019502302A1 (enExample)
SG (1) SG11201909041SA (enExample)
WO (1) WO2018195226A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7497351B2 (ja) * 2018-11-13 2024-06-10 コンパス セラピューティクス リミテッド ライアビリティ カンパニー チェックポイント分子に対する多重特異性結合性構築物およびその使用
CN113646330A (zh) 2018-11-14 2021-11-12 鲁比克治疗股份有限公司 工程化cd25多肽及其用途
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
CN109929037B (zh) 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
JP7302010B2 (ja) * 2019-04-11 2023-07-03 スクリップス コリア アンチボディ インスティチュート プログラム細胞死タンパク質リガンド－１（ｐｄ－ｌ１）に対する抗体及びその用途
SG11202103000WA (en) * 2019-04-26 2021-04-29 I Mab Biopharma Us Ltd Human pd-l1 antibodies
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
CA3187850A1 (en) 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
WO2023046113A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US10202454B2 (en) * 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
WO2015103602A1 (en) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CA3265373A1 (en) * 2014-02-20 2025-10-30 H. Lundbeck A/S Anti-acth antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
JP7011657B2 (ja) * 2016-10-30 2022-02-10 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｐｄ－ｌ１抗体および変異型

Also Published As

Publication number Publication date
CO2019012118A2 (es) 2020-04-01
WO2018195226A1 (en) 2018-10-25
CL2019002953A1 (es) 2020-01-10
US20210115143A1 (en) 2021-04-22
EP3612565A1 (en) 2020-02-26
CA3059447A1 (en) 2018-10-25
SG11201909041SA (en) 2019-11-28
JP2023025003A (ja) 2023-02-21
BR112019021828B1 (pt) 2022-09-20
EA201900443A1 (ru) 2020-03-06
EP3612565A4 (en) 2021-06-16
PH12019502302A1 (en) 2020-09-21
MX2019012461A (es) 2019-12-11
AU2018256392B2 (en) 2024-05-16
BR112019021828A2 (pt) 2020-03-24
MA50038A (fr) 2020-07-08
KR20190141169A (ko) 2019-12-23
JP2020517239A (ja) 2020-06-18
AU2018256392A1 (en) 2019-10-17
KR102323960B1 (ko) 2021-11-10
CN110856446A (zh) 2020-02-28

Similar Documents

Publication Publication Date Title
PH12019502302A1 (en) Anti-pd-l1 antibody and use thereof
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
MX2025009209A (es) Anticuerpos de b7-h4 y metodos para usarlos
SA523442262B1 (ar) أجسام مضادة للارتباط بـ cd3
MX2024005027A (es) Anticuerpos de union a cd3.
EA201491700A1 (ru) Человеческие антитела к cd27, методы и применение
PH12021552002A1 (en) Anti-trem2 antibodies and methods of use thereof
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
NZ631543A (en) Antibodies to bradykinin b1 receptor ligands
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
NZ704269A (en) Rspo3 binding agents and uses thereof
HK1216850A1 (zh) 抗ntb-a抗體及相關的組合物和方法
MY187325A (en) Anti-5t4 antibodies and antibody-drug conjugates
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2024005669A (es) Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.
WO2020168231A3 (en) Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses
NZ601943A (en) Antibodies against cxcr4
MX2025001934A (es) UN ANTICUERPO HUMANIZADO QUE TIENE ESPECIFICIDAD DE UNIÓN PARA LA INTEGRINA A4ß7 HUMANA PARA USARSE EN LA PREVENCIÓN O REDUCCIÓN DE LA APARICIÓN DE GVHD AGUDA EN UN PACIENTE HUMANO QUE TIENE ALL O AML Y QUE SE SOMETE A ALLO-HSCT
NZ602515A (en) Proteins that bind pi16 and uses thereof
PH12022550765A1 (en) Binding molecule specific for lif and use thereof